BeOne's Brukinsa Remains Best-In-Class Drug for Chronic Lymphocytic Leukemia

BeOne is an emerging Chinese biotechnology company with a leading global position in hematologic cancers, thanks to its core drug Brukinsa. Since its approval in 2019, Brukinsa’s stronger efficacy and superior safety profile have allowed BeOne to gain market share from existing drugs. We perceive Brukinsa to be the best-in-class drug treatment for chronic lymphocytic leukemia as well as other lymphoma cancers based on statistically significant results compared with its closest competitor, AbbVie's Imbruvica.